

A Report From The NIHR UK Working Group On Remote Trial Delivery For The COVID-19 Pandemic and Beyond

Masoli, J

<http://hdl.handle.net/10026.1/19262>

10.21203/rs.3.rs-591653/v1

All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

Trials

A report from the NIHR UK working group on remote trial delivery for the COVID-19 pandemic and beyond --Manuscript Draft--

Manuscript Number:	
Full Title:	A report from the NIHR UK working group on remote trial delivery for the COVID-19 pandemic and beyond
Article Type:	Commentary
Funding Information:	National Institute for Health Research Dr Jane Masoli
Abstract:	<p>Background</p> <p>Prior to the COVID-19 pandemic, the majority of clinical trial activity took place face to face within clinical or research units. The COVID-19 pandemic resulted in a significant shift towards trial delivery without in person face to face contact or “Remote Trial Delivery”. The National Institute of Health Research (NIHR) assembled a Remote Trial Delivery Working Group to consider challenges and enablers to this major change in clinical trial delivery and to provide a toolkit for researchers to support the transition to remote delivery.</p> <p>Methods</p> <p>The NIHR Remote Trial Delivery Working Group evaluated five key domains of the trial delivery pathway: participant factors, recruitment, intervention delivery, outcome measurement and quality assurance. Independent surveys were disseminated to research professionals, and patients and carers, to ascertain benefits, challenges, pitfalls, enablers and examples of good practice in Remote Trial Delivery. A toolkit was constructed to support researchers, funders and governance structures in moving towards Remote Trial Delivery. The toolkit comprises a website encompassing the key principles of Remote Trial Delivery, and a repository of best practice examples and questions to guide research teams.</p> <p>Results</p> <p>The patient and carer survey received 47 respondents, 34 of whom were patients and 13 of whom were carers. The professional survey had 115 examples of remote trial delivery practice entered from across England. Key potential benefits included broader reach and inclusivity, the ability for standardisation and centralisation, and increased efficiency and patient/carer convenience. Challenges included the potential exclusion of participants lacking connectivity or digital skills, the lack of digitally skilled workforce and appropriate infrastructure, and validation requirements. Five key principles of Remote Trial Delivery were proposed: national research standards, inclusivity, validity, cost-effectiveness and evaluation of new methodologies.</p> <p>Conclusions</p> <p>The rapid changes towards Remote Trial Delivery catalysed by the COVID-19 pandemic could lead to sustained change in clinical trial delivery. The NIHR Remote Trial Delivery Working Group provide a toolkit for researchers recommending five key principles of Remote Trial Delivery and providing examples of enablers.</p>
Corresponding Author:	Camille Carroll University of Plymouth UNITED KINGDOM
Corresponding Author E-Mail:	camille.carroll@plymouth.ac.uk
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	University of Plymouth

Corresponding Author's Secondary Institution:	
First Author:	Jane Masoli
First Author Secondary Information:	
Order of Authors:	Jane Masoli
	Sharon Hudson
	John T O'Brien
	James D Williamson
	Carolyn A. Young
	Camille Carroll
Order of Authors Secondary Information:	
Opposed Reviewers:	
Additional Information:	
Question	Response
Are you submitting this manuscript to a Thematic Series?	No

[Click here to view linked References](#)

**A report from the NIHR UK working group on remote trial delivery for the COVID-19
pandemic and beyond**

Jane AH Masoli^{1,2}, Sharon Hudson³, John T O'Brien^{4,5}, James D Williamson⁶, Carolyn A.
Young^{7,8} and Camille Carroll⁹ on behalf of the NIHR Remote Trial Delivery Working Group

¹Royal Devon and Exeter NHS Foundation Trust

²College of Medicine and Health, University of Exeter

³Cornwall Partnership NHS Foundation Trust

⁴Department of Psychiatry, University of Cambridge School of Clinical Medicine

⁵Cambridgeshire and Peterborough NHS Foundation Trust

⁶National Institute for Health Research

⁷Walton Centre NHS Foundation Trust

⁸University of Liverpool

⁹University of Plymouth

Corresponding author: Camille Carroll camille.carroll@plymouth.ac.uk

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Background

Prior to the COVID-19 pandemic, the majority of clinical trial activity took place face to face within clinical or research units. The COVID-19 pandemic resulted in a significant shift towards trial delivery without in person face to face contact or “Remote Trial Delivery”. The National Institute of Health Research (NIHR) assembled a Remote Trial Delivery Working Group to consider challenges and enablers to this major change in clinical trial delivery and to provide a toolkit for researchers to support the transition to remote delivery.

Methods

The NIHR Remote Trial Delivery Working Group evaluated five key domains of the trial delivery pathway: participant factors, recruitment, intervention delivery, outcome measurement and quality assurance. Independent surveys were disseminated to research professionals, and patients and carers, to ascertain benefits, challenges, pitfalls, enablers and examples of good practice in Remote Trial Delivery. A toolkit was constructed to support researchers, funders and governance structures in moving towards Remote Trial Delivery. The toolkit comprises a website encompassing the key principles of Remote Trial Delivery, and a repository of best practice examples and questions to guide research teams.

Results

The patient and carer survey received 47 respondents, 34 of whom were patients and 13 of whom were carers. The professional survey had 115 examples of remote trial delivery practice entered from across England. Key potential benefits included broader reach and inclusivity, the ability for standardisation and centralisation, and increased efficiency and patient/carer convenience. Challenges included the potential exclusion of participants lacking connectivity or digital skills, the lack of digitally skilled workforce and appropriate infrastructure, and validation requirements. Five key principles of Remote Trial Delivery were

1 proposed: national research standards, inclusivity, validity, cost-effectiveness and evaluation
2 of new methodologies.
3

4 **Conclusions**

5
6
7
8 The rapid changes towards Remote Trial Delivery catalysed by the COVID-19 pandemic
9
10 could lead to sustained change in clinical trial delivery. The NIHR Remote Trial Delivery
11
12 Working Group provide a toolkit for researchers recommending five key principles of Remote
13
14 Trial Delivery and providing examples of enablers.
15
16

17 **Keywords**

18
19
20 Remote trial delivery; virtual research; trial methodology; remote research
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Background

1
2
3 Even before the COVID-19 pandemic, the traditional model of clinical trial delivery confined
4
5 to the research unit was starting to slowly change. Delivery of clinical trials outside the
6
7 hospital or research unit reduces some of the barriers to participation in clinical research and
8
9 is aligned with the National Institute of Health Research (NIHR) project Innovations in
10
11 Clinical Trial Design and Delivery for the Under-served (INCLUDE)(1), aiming towards
12
13 greater inclusivity in clinical research. Restricting trials to those with the time, fitness and
14
15 willingness to travel to research settings restricts potential participants, introducing bias. This
16
17 can be due to distance from the research site, reduced mobility or ill health, challenges with
18
19 transport or external commitments such as work or caring responsibilities(2,3). Delivery of
20
21 clinical trials remotely for those who could not attend these settings had been slowly
22
23 increasing prior to the start of the COVID-19 pandemic. Remote formats included telephone
24
25 follow-up, online patient recruitment and interventions(4,5). Initiatives such as Trials@Home
26
27 were aiming to develop standards and make recommendations on remote delivery and
28
29 decentralisation of clinical trials(5).
30
31
32
33

34
35 The COVID-19 pandemic necessitated rapid, radical changes in clinical trial delivery. There
36
37 was an immediate risk to public health, vulnerable groups were shielded, healthier
38
39 participants were wary of hospital environments, and use of research facilities was restricted
40
41 to minimise co-working and person to person contact. The European Medicines Agency
42
43 (EMA)(6) and the US Food and Drug Administration (FDA)(7) issued rapid guidance on
44
45 assuring participant safety, maintaining compliance with good clinical practice (GCP) and
46
47 minimising the risk to trial integrity. Worldwide, clinical researchers were forced to reconsider
48
49 and restructure clinical trial protocols to make them workable and safe during a pandemic.
50
51 This meant transferring as many aspects of the clinical trial as was considered safe and valid
52
53 to remote delivery to minimise travel and potential exposure. However, not all sites or
54
55 investigators had sufficient knowledge, facilities, infrastructure and familiarity of remote
56
57
58
59
60
61
62
63
64
65

1 processes to make these considerable system changes, and disparate research groups met
2 and addressed challenges independently.
3

4
5 The NIHR Clinical Research Network, which supports participation in high-quality research
6 across England, formed a Remote Trial Delivery Working Group to consider the impact of a
7 transition to remote trial delivery at each stage of the clinical trial process. The aim of this
8 Working Group was to facilitate sharing of knowledge and best practice, addressing
9 participant safety and concerns were central to the work. We aimed to collate information on
10 practice of remote delivery of clinical trials, in the context of rapid pandemic-related system
11 change. We also aimed to establish key principles of Remote Trial Delivery, and to produce
12 a toolkit to address potential challenges and provide examples of good practice for clinical
13 researchers, funders and governance agencies to use when planning remote delivery of
14 clinical trials. Whilst the focus of the group was on clinical trials (i.e. studies with an
15 intervention), findings from the toolkit may be equally applicable to many other clinical
16 studies.
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 **Methods**

32
33 A national Remote Trial Delivery Working Group was formed by the NIHR in July 2020.
34
35 Stakeholders included patient and public representatives, colleagues from across the clinical
36 research network including from business development and marketing, research delivery
37 and specialties such as ageing, genetics, neurological disorders and dementia, as well as
38 colleagues from industry.
39
40
41
42
43
44
45
46

47 **Defining Remote Trial Delivery**

48
49 The initial approach of the group was to establish a consensus definition of Remote Trial
50 Delivery for the purpose of the work. We agreed that “Remote Trial Delivery” should include
51 all activities related to clinical trial delivery undertaken without in person, face to face
52 contact.
53
54
55
56
57
58
59
60
61
62
63
64
65

The trial delivery pathway


We formed 5 subgroups based on the key domains of the trial delivery pathway: participant factors, recruitment, intervention delivery, outcome measurement and quality assurance, as detailed in figure 1.



Figure 1: Key domains of clinical trial delivery

In order to establish the potential benefits and pitfalls of Remote Trial Delivery, as well as challenges and enablers, each subgroup extracted examples from the two surveys outlined below, as well as reviewing NIHR case studies on restarting research(8) and pragmatic searching for additional studies that provided examples of remote delivery pertinent to that specific domain of the clinical trial pathway. The accumulated evidence was then streamlined into factors affecting participant experience, infrastructure and processes, and assessments and interventions. The key principles of Remote Trial Delivery were

1 established through initial Working Group discussion with an iterative approach following
2 subgroup refinement of existing practice within their domain.
3
4
5
6
7
8
9



33
34 Figure 2: Working group work process between September 2020 and December 2020, with
35 deliverables refined January to March 2021
36
37

38 Surveys

39
40
41 We designed two surveys that were disseminated concurrently in September 2020 to
42 capture information on remote delivery across the clinical trial pathway. Both surveys were
43 implemented in order to ascertain challenges, enablers and examples of good practice, the
44 first from participants and carers and the second from researchers and research delivery
45 teams. Researchers were also asked to identify the greatest area of need in order to inform
46 remote trial delivery. The surveys were created in Google forms with anonymised data
47 capture and hosted by the NIHR. The researcher surveys were disseminated through
48 national and regional Clinical Research Network newsletters, as well as through the cluster
49 offices to their respective specialty leads to share wherever possible.
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 The participant and carer survey was co-developed with the NIHR patient and public
2 involvement (PPI) representatives, and was circulated via the NIHR PPI network, social
3 media, dissemination via NIHR CRN networks and via the Association of Medical Charities
4 to their members. The surveys were available from September to November 2020.
5
6
7
8

9 **Development of the NIHR Remote Trial Delivery Toolkit**

10 We used the results from the methods detailed above to develop a toolkit for researchers
11 seeking to make the transition to Remote Trial Delivery. A website was developed and
12 launched in March 2021(9), hosted by the NIHR, which encompasses the key principles of
13 Remote Trial Delivery, and a repository of best practice examples, which were collated by
14 this Working Group. In addition the website includes questions to guide research teams in
15 designing and delivering remote trials (Table 1).
16
17
18
19
20
21
22
23
24
25

26	1. Do you need to change the way in which you identify potential participants? 27 Has the clinical care pathway changed?																																
28	2. What are the infrastructure requirements for the proposed method of 29 delivery (hardware, software, connectivity)? Are these supported by your 30 organisation and available to potential participants?																																
31	3. Will Remote Trial Delivery introduce bias? If so, how can this be mitigated?																																
32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65
	4. Are you able to provide participants with guidance and support in using the remote methods?																																
	5. How will you ensure participants feel supported and have the opportunity to ask questions?																																
	6. What training provision is there for your team and participants in any new methodologies?																																
	7. Are the interventions, assessments and outcome measures validated for the planned use?																																
	8. Will some aspects of trial delivery be more difficult (e.g. some safety assessments)? How will this be mitigated?																																
	9. Are there any concerns regarding data security as a result of remote delivery?																																
	10. Do you need to adapt your processes to ensure data integrity?																																
	11. What additional processes for PI oversight do you need to develop?																																

1
2
3 Table 1: Questions to guide research teams in designing and delivering remote trials
4
5
6
7

8 **Results**
9

10
11
12 **Patient and carer survey**
13
14

15 There were 47 respondents to the patient and carer survey, 34 of whom were patients and
16
17 13 of whom were carers. Respondents were from across England (the area covered by the
18
19 NIHR), with all adult age groups represented, including eight aged over 75 years. 34 (72%)
20
21 were women. 32 (68%) had had experience of remote delivery of at least one aspect of a
22
23 clinical trial (online or by post or telephone). The patients and carers were asked to consider
24
25 the advantages and disadvantages of Remote Trial Delivery and to cite any personal
26
27 examples. From this we were able to develop themes of advantages and disadvantages of
28
29 Remote Trial Delivery from the participant perspective, and we combined these themes with
30
31 the results of the professional survey and pragmatic scoping searches. The key themes of
32
33 potential advantages and disadvantages of Remote Trial Delivery from the patient and carer
34
35 perspective supported by examples of survey extracts are summarised in Table 2.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

(a) Advantages of remote trial delivery

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Time	<p>“can complete in own time”</p> <p>“better for working age participants as saves time”</p> <p>“less time waiting around”</p> <p>“have time to consider answers”</p> <p>“no time pressures”</p> <p>“less disruption to carers”</p> <p>“don’t have to rearrange childcare”</p>
Feeling safe	<p>“less anxiety for him”</p> <p>“reduced risk of COVID infection”</p> <p>“feeling of safety not going into hospital”</p> <p>“relaxed when dealing with researchers”</p> <p>“in my own comfort zone”</p> <p>“less stress about the appointment so anxiety levels lower”</p>
Travel and transport	<p>“convenience of not travelling”</p> <p>“no parking problems”</p> <p>“no stress getting to appointments on time”</p> <p>“no travel prep or stress so clearer results for researchers (meaning assessment is not of the travel stress but of his actual condition)”</p>
Accessibility	<p>“being able to join in when there may not be much research happening nearby”</p> <p>“being able to do the study anywhere in the country”</p> <p>“rapid response to any problems arising”</p> <p>“good for people who can’t go out”</p> <p>“can still contribute”</p> <p>“can take part 24/7”</p>

(b) Disadvantages of remote trial delivery

Inclusivity	<p>“may exclude certain groups in the population”</p> <p>“patient participants rarely representative of all social & cultural groups”</p>
IT	<p>“some glitches”</p> <p>“accessing the website wasn’t easy”</p> <p>“wifi is terrible (rural)”</p> <p>“not used to technology”</p>
Communication	<p>“(missed) seeing peoples’ full body language”</p> <p>“difficult to hear”</p> <p>“it needs to be easy enough to understand and follow remotely”</p> <p>“you don’t get contact...chat and fun with the nurses”</p>
Validity	<p>“not sure how the assessment scores compared to those face to face”</p> <p>“unable to collect most of the study outcomes”</p> <p>“the telephone follow-up was perfunctory”</p> <p>“questionnaires repeated often – no change to report – difficult to be consistent”</p> <p>“If treatment or medication was being assessed I’d prefer face to face contact”</p>
Support	<p>“difficult to get help with tasks”</p> <p>“not having anyone to contact in the event of a problem”</p> <p>“I didn’t feel particularly supported”</p> <p>“any questions arising had to be raised at a later date”</p> <p>“lack of potential support”</p> <p>“nobody to answer questions or provide help in case of problems”</p>
Value	<p>“feeling like a number in a study so not feeling valued as a participant”</p> <p>“impersonal”</p>

Table 2: Key themes of (a) advantages and (b) disadvantages of remote trial delivery from the patient and carer perspective, with example extracts from the survey

Professional survey

The survey included 115 examples of remote trial delivery practice entered by respondents from 13 of the 15 local CRN regions in England. Respondents represented primary and secondary care research, with a broad reach across 28 clinical specialties. The research professionals identified patient experience as the aspect of Remote Trial Delivery most in need of further evidence to inform future successful remote delivery of studies, followed by outcome measures and quality assurance, and then recruitment, with intervention ranked as having the least need. The themes of identified uncertainties, knowledge gaps and developments required are summarised in Table 3.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Identified uncertainties, knowledge gaps and developments required

1		
2		
3	Technology	Electronic site files
4		Integration between electronic systems
5		Digital consent
6		Data security, storage and access
7		Digital signatures
8		
9		
10	Training and skill development	Research teams
11		Participants
12		
13	Communication	Digital communication
14		- with participants
15		- between participants
16		- between sites
17		- between researchers
18		- with the NHS: records, systems, healthcare
19		workers
20		
21	Validity	Consent process
22		Interventions
23		Study measures
24		
25	Participant factors	Safety
26		Acceptability
27		Bias/exclusion
28		Support
29		Impact on recruitment
30		Valid consent
31		Retention in trials
32		Return to future trials
33		
34	Governance	Standardisation
35		Quality
36		Data security
37		Sponsor and regulator support for remote processes
38		
39	Resources	Time compared to “traditional” model
40		Cost compared to “traditional” model
41		“Buy-in” from sponsors
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		
61		
62		
63		
64		
65		

Table 3: Uncertainties or knowledge gaps identified by research professionals and developments required to facilitate effective Remote Trial Delivery

Benefits, pitfalls, challenges and enablers of remote trial delivery across the research pathway

The working group identified key benefits, pitfalls, challenges and enablers to Remote Trial Delivery across the trial pathway utilising examples from the two surveys combined with scoping literature reviews (Table 4). In order to guide sites and researchers in thinking through the challenges, a series of questions was developed and posted within the toolkit on the website, together with case study illustrations of where particular processes have been successfully deployed.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

	Benefits	Pitfalls	Challenges	Enablers
<i>Participant experience</i>	<p>Broader reach and inclusivity (in IT enabled groups); increased research opportunity</p> <p>Flexibility in study delivery, increased convenience (e.g. not having to arrange transport and parking at study site)</p> <p>Reduced infection risk</p> <p>Socially or geographically targeted recruitment</p>	<p>The impression of being ‘alone’ (unsupported)</p> <p>Reduced contact with study team might impact on retention</p> <p>Potential for non-compliance (intentional and unintentional)</p> <p>Potential for bias (e.g. due to limitations in remote communication e.g. computer literacy (digital divide, age-related/socio-economic), literacy, audio-visual impairments))</p> <p>Reduced ability to ask questions or seek clarification</p> <p>Loss of non-verbal communication/difficulty with holistic assessment</p>	<p>Digital infrastructure and literacy</p> <p>Pathways to approach potential participants/care partners</p> <p>Adaptations required for inclusivity – e.g. hearing, visual or cognitive impairment</p> <p>Failure to maintain participant engagement</p> <p>Communication, including post-trial</p>	<p>Digital infrastructure and literacy</p> <p>Provision of guidance and support with technology and trouble-shooting</p> <p>Ensuring participant well-prepared and followed-up regularly</p> <p>Provision of guidance and training on protocol adherence</p> <p>Peer support opportunities for participants (e.g. virtual coffee mornings)</p> <p>Safety net of regular video contact</p> <p>Clear route for communicating with the study team</p>
<i>Infrastructure and processes</i>	<p>Can be standardised/centralised</p> <p>Improved efficiency</p>	<p>Threat to privacy/confidentiality</p> <p>Data security</p> <p>Protocol compliance more difficult to assess</p>	<p>Outdated NHS IT systems (NHS IT – National Health Service Information Technology)</p> <p>Quality control/standardisation harder to ensure in diverse environments</p>	<p>Electronic patient/medical record/HSCN (Health and Social Care Network)</p> <p>Standardised processes (e.g. FHIR Fast Healthcare Interoperability Resources)</p>

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

**Assessments
and
interventions**

			<p>More resource-demanding Increased preparation time for remote monitoring</p> <p>Variation in information governance processes and standards</p> <p>Maintenance of essential documentation</p>	<p>Approved e-consent process</p> <p>Central coordination</p> <p>Consent and ethics approval in place for remote monitoring</p> <p>Flexible mind-set within organisations</p> <p>Experienced workforce with appropriate skills</p>
<p>Greater ecological validity</p> <p>Potentially greater clinical validity than 'snap-shot' in-clinic assessments</p> <p>Captured with greater granularity</p> <p>Reduced data capture error</p> <p>Reduced risk of research fraud</p> <p>More efficient data analysis.</p>	<p>May not be validated</p> <p>Potential for reduced safety assessments</p> <p>Potential for increased heterogeneity within measurements</p>	<p>Unsupervised environment for delivery</p> <p>Requirement for demonstration of validity/equivalence</p> <p>Need to be acceptable to regulators</p> <p>Lack of staff familiarity</p> <p>Should be feasible and acceptable to patients</p> <p>Not all interventions can be delivered remotely</p>	<p>Developed and validated for remote delivery</p> <p>Equivalence to traditional measure demonstrated</p>	

Table 4: Benefits, pitfalls, challenges and enablers of Remote Trial Delivery

Key principles of Remote Trial Delivery

The NIHR Remote Trial Delivery Working Group refined five key principles of Remote Trial Delivery, supported by the results of the surveys conducted in participants and carers and research professionals.

These principles are:

1. National standards for trial delivery best practice should apply
2. Inclusivity should be maximised
3. Measures and processes should be validated
4. Trial delivery should be cost effective
5. New methodologies should be robustly evaluated

Discussion

The COVID-19 pandemic had an immediate impact on clinical trial delivery, and provided an opportunity for rapid, systemic change. There was an immediate removal of former barriers to restructuring towards a remote delivery approach. The Remote Trial Delivery Working Group recommended five key principles of Remote Trial Delivery and developed a toolkit to guide researchers, underpinned by a targeted literature review and surveys of research professionals, participants and carers. As well as the key principles and toolkit, we have assembled a repository of good practice examples available on our website.

The speed of change away from face to face delivery without clear methods and signposting undoubtedly led to rapid development of innovations in research planning and delivery, from which valuable lessons can be learned. The wider societal shift to remote working has provided considerable upskilling in digital communications and introduced innovative, technology-supported ways of working, reducing the need for physical meetings. Participants and researchers described significant benefits of remote delivery of some aspects of clinical trials in addition to reduced COVID-19 infection risk. For example, broader reach and

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

inclusivity in IT enabled groups, and improved efficiency and flexibility for both research teams and participants. In addition, once the infrastructure is sufficient to support remote trial delivery with centralisation of processes, Remote Trial Delivery is likely to reduce the costs and environmental impact of clinical research.

However, the benefits of Remote Trial Delivery are not universal, and significant knowledge gaps remain. Importantly, Remote Trial Delivery most frequently involves the use of online platforms, or applications, which can introduce bias in participant recruitment and ability to participate. The “digital divide” is the gap between people in society who have full access or skills to enable use of digital technologies, such as the internet and computers, and those who do not(10). In the UK the main factors influencing the digital divide are age, region, socioeconomic status and whether a person has a disability(10). Following COVID19, research will be needed to establish how the wider use of internet and video conferencing has altered access and familiarity with online communication. This should be considered when planning and delivering clinical trials. It is also essential to have a digitally literate and competent workforce to deliver clinical trials remotely, for all aspects of clinical trial delivery including ensuring a good quality patient experience. This will require the right platforms, processes and infrastructure. For example, access to electronic healthcare records for remote monitoring, the ability to store, manage and transfer electronic documents and appropriate electronic consent platforms.

The research professionals survey respondents did not consider the intervention as a leading trial component in need of further evidence in order to provide Remote Trial Delivery. In some trials – for example drug trials - the intervention delivery may not be significantly altered by remote delivery, which may be why this was not considered a higher priority. However, a major potential limitation of Remote Trial Delivery is that there is currently insufficient evidence to support the validity of many specific interventions and assessments when delivered remotely and more research is required. Equally, quality assurance processes need to continue to be rigorous, including monitoring of data integrity and

oversight processes sufficient to meet the appropriately high standards of regulators.

Providing sufficiently rigorous regulation while enabling innovation is a further challenge.

Standards for metadata to support digital health technologies in clinical research(11) and frameworks for Biometric Monitoring Technologies(12) have been proposed. However, there is no formal standard that is widely accepted. In addition, the participant voice in not feeling valued in the same way as in previous trial experiences or having the same personal interactions with the research team may impact on the recognised benefit of being enrolled in clinical trials regardless of intervention group, as well as reducing willingness to participate and retention in follow up.

The potential advantages and disadvantages of Remote Trial Delivery that we have outlined are in keeping with previous reports. The Trials@Home group released a first set of recommendations for remote delivery of clinical trials in August 2020(13), based on systematic literature review and a consortium of public and private partners. The themes that they described of potential advantages and limitations correlate well with our findings. There is a growing industry drive to decentralisation and remote delivery of clinical trials citing improved participation opportunity, trial efficiency and quality, with some of the transformation and decentralisation drives receiving cross-sector support including government, patient groups, sponsors, professional societies and academic institutions(14).

Strengths

This NIHR Remote Trial Delivery Working Group formed from a broad range of national stakeholders has delivered a consensus opinion on the key principles of Remote Trial Delivery and a toolkit for researchers to use when planning remote delivery. This work included patient and participants as key members of the Working Group and designed and implemented separate surveys for participants and research professionals. This adhered to the goal of keeping the participant as the central focus of this work. This approach enabled us to present the participant views, as well as the overall themes of potential advantages and disadvantages of Remote Trial Delivery.

Limitations

1
2
3 Similar to the report from the INCLUDE group(1), the Remote Trial Delivery Working Group
4 conducted this work as a focussed, time-limited project. This work needed to be expedited to
5 provide a toolkit and recommendations at a crucial period of service re-design in clinical trial
6 delivery due to the COVID-19 pandemic. This led to some compromise in the approach.
7

8
9 Firstly, the literature was not reviewed using a prespecified protocol or a systematic search.
10

11
12 Secondly, surveys, while widely circulated via national networks, were time limited and
13 targeted. We recognise that the participants and carers surveyed represent those on the
14 privileged side of the digital divide and are not a representative sample of the overall
15 participant population.
16
17

Future steps

18
19 Further research is required across the research pathway to establish the scientific
20 robustness of Remote Trial Delivery, as well as ensuring that the quality of the participant
21 experience is maintained. This should include validation studies for specific methods and
22 outcome measures, alongside work to assure data quality across the trial pathway. This
23 should be tailored to whether the measure is an existing measurement applied to a different
24 setting e.g. home setting replication, or whether it is a new measure incorporating digital
25 measurement or a novel concept or end point.
26
27

28
29 We have identified knowledge gaps and developments required in order to optimise the
30 potential for Remote Trial Delivery. These include changes in processes, infrastructure and
31 workforce, especially with technology, data and training. Clinical trial delivery will need to
32 evolve to clinical care pathways of the future, in accordance with the NHS Long Term
33 Plan(15) in which digitally enabled care will be mainstream. We need to ensure that we build
34 the infrastructure and skills now to support the delivery of hybrid or fully remote clinical trials,
35 building on the principles described.
36
37

Conclusion

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 The transition towards Remote Trial Delivery was an unanticipated consequence of the
2 COVID-19 pandemic. Remote Trial Delivery has potential benefits for research teams and
3 participants, but the recommended five key principles (national research standards,
4 inclusivity, validity, cost-effectiveness and evaluation of new methodologies) should be
5 adhered to, to ensure scientific robustness and participant safety. Transitioning to Remote
6 Trial Delivery requires adequate planning, and we have provided a toolkit to highlight
7 potential challenges and barriers, with examples of enablers and further examples of best
8 practice available on our website. In the medium to longer term, clinical trials are likely to
9 operate in a spectrum from traditional model to full remote delivery, with the majority of trials
10 operating some components remotely. Clinical trial delivery has been impacted by COVID-
11 19, but with it has come the opportunity for change and to retain positive practices in Remote
12 Trial Delivery to be fit for purpose for the future.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

1. Witham MD, Anderson E, Carroll C, Dark PM, Down K, Hall AS, et al. Developing a roadmap to improve trial delivery for under-served groups: results from a UK multi-stakeholder process. *Trials* [Internet]. 2020 Dec 1 [cited 2021 Mar 5];21(1):694. Available from: <https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04613-7>
2. Baquet CR, Commiskey P, Daniel Mullins C, Mishra SI. Recruitment and participation in clinical trials: socio-demographic, rural/urban, and health care access predictors. *Cancer Detect Prev* [Internet]. 2006 [cited 2021 Mar 2];30(1):24–33. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/16495020>
3. Walsh E, Sheridan A. Factors affecting patient participation in clinical trials in Ireland: A narrative review. *Contemp Clin trials Commun* [Internet]. 2016 Aug 15 [cited 2021 Mar 2];3:23–31. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/29736453>
4. Brøgger-Mikkelsen M, Ali Z, Zibert JR, Andersen AD, Thomsen SF. Online Patient Recruitment in Clinical Trials: Systematic Review and Meta-Analysis. *J Med Internet Res* [Internet]. 2020 [cited 2021 Mar 2];22(11):e22179. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33146627>
5. Trials@Home – Centre of Excellence Remote and Decentralised Clinical Trials [Internet]. [cited 2021 Apr 27]. Available from: <https://trialsathome.com/>
6. European Medicines Agency. Guidance on the Management of Clinical Trials During the Covid-19 (Coronavirus) Pandemic. 2020;19:2019–21.
7. FDA. FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency: Guidance for Industry, Investigators, and Institutional Review Boards. 2020;March; updated 11 May 2020. Available from: <https://www.fda.gov/regulatory-%0Ahttps://www.fda.gov/regulatory->

%0Ahttps://www.fda.gov/media/136238/download

- 1
2
3 8. National Institute for Health Research. Restarting research - Recovery, Resilience
4 and Growth [Internet]. [cited 2021 May 30]. Available from:
5
6
7 <https://local.nihr.ac.uk/restarting-research/>
8
9
- 10 9. NIHR. NIHR Remote Trial Delivery [Internet]. Available from:
11
12 <https://sites.google.com/nihr.ac.uk/remotetrialdelivery/home>
13
14
- 15 10. Baker C, Hutton G, Christie L, Wright S. COVID-19 and the digital divide [Internet].
16
17 [cited 2021 Mar 5]. Available from: [https://post.parliament.uk/covid-19-and-the-digital-](https://post.parliament.uk/covid-19-and-the-digital-divide/)
18
19 [divide/](https://post.parliament.uk/covid-19-and-the-digital-divide/)
20
21
- 22 11. Badawy R, Hameed F, Bataille L, Little MA, Claes K, Saria S, et al. Metadata
23
24 Concepts for Advancing the Use of Digital Health Technologies in Clinical Research.
25
26 Digit biomarkers [Internet]. 2019 [cited 2021 Mar 26];3(3):116–32. Available from:
27
28 <http://www.ncbi.nlm.nih.gov/pubmed/32175520>
29
30
31
- 32 12. Goldsack JC, Coravos A, Bakker JP, Bent B, Dowling A V, Fitzer-Attas C, et al.
33
34 Verification, analytical validation, and clinical validation (V3): the foundation of
35
36 determining fit-for-purpose for Biometric Monitoring Technologies (BioMeTs). NPJ
37
38 Digit Med [Internet]. 2020 [cited 2021 Mar 26];3:55. Available from:
39
40 <http://www.ncbi.nlm.nih.gov/pubmed/32337371>
41
42
43
- 44 13. Rogers A, Mackenzie I, Hawkins K. First set of recommendations for RDCTs (to be
45
46 implemented in the pan-EU pilot RDCT). 2020;1–46.
47
48
- 49 14. Clinical Trials Transformation Initiative | [Internet]. [cited 2021 Mar 26]. Available from:
50
51 <https://www.ctti-clinicaltrials.org/>
52
53
- 54 15. NHS. NHS Long Term Plan » Online version of the NHS Long Term Plan [Internet].
55
56 [cited 2021 Mar 26]. Available from: <https://www.longtermplan.nhs.uk/online-version/>
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Declarations

Ethics approval and consent to participate: not required.

Consent for publication: not required

Availability of data and materials: surveys included in supplementary material. Data are available from the authors upon reasonable request.

Competing interests Nil

Funding

Dr Jane Masoli is funded by the National Institute for Health Research (NIHR), (NIHR Development and Skills Enhancement Fellowship, NIHR301445). This publication presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Carolyn A. Young reports research grants from MND Association and personal consulting fees from Cytokinetics and Orion.

Authors' contributions

The Remote Trial Working Group performed the work detailed, led by CC with workstreams led by JM, SH, J O'B, JW & CY. JM & CC drafted the paper with input from SH, J O'B, JW & CY. The Remote Trial Working Group refined the manuscript and approved the final version.

Acknowledgements

Remote Trial Delivery Working Group

Name	Organisation	Subgroup
Benjamin R Underwood	Department of Psychiatry, University of Cambridge NIHR Dementia National Specialty Group	Outcome measures

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Ross Dunne	Greater Manchester Mental Health NHS Foundation Trust NIHR Dementia National Specialty Group	Quality Assurance
John O'Brien	University of Cambridge School of Clinical Medicine Cambridgeshire and Peterborough NHS Foundation Trust	Intervention
Shane McKee	NIHR Genetics National Specialty Group	Outcome measures
Eamonn R Maher	Department of Medical Genetics, School of Clinical Medicine, University of Cambridge NIHR Genetics National Specialty Group	Recruitment
Khalid Ali	Brighton and Sussex Medical School NIHR Ageing National Specialty Group	Recruitment
Jane Masoli	University of Exeter Royal Devon and Exeter NHS Trust NIHR Ageing National Specialty Group	Patient Experience
Miles D Witham	AGE Research Group, NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle upon Tyne Hospitals NHS Foundation Trust NIHR Ageing National Specialty Group	Outcome measures
Camille Carroll	University of Plymouth NIHR Neurodegeneration National Specialty Group	Remote Trial Working Group Chair
Chris J McDermott	University of Sheffield NIHR Neurodegeneration National Specialty Group	Quality Assurance
Stacy Young	University of Sheffield NIHR Neurodegeneration National Specialty Group	Intervention

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Carolyn Young	Walton Centre NHS Foundation Trust University of Liverpool NIHR Neurological Disorders National Specialty Group	Outcome measures
Denise Wilson	NIHR Business Development Manager Clinical Research network	
Lynn Rochester	NIHR Cluster E	Outcome measures
Peter Goadsby	Kings College London Neurological Disorders National Specialty Group	Intervention
James D Williamson	NIHR Research Delivery Lead	Recruitment
Sharon Hudson	Clinical Research Specialty Lead Mental Health South West Peninsula Cornwall Partnership NHS Foundation Trust	Quality Assurance
Kevin McFarthing	Independent Parkinson's Research Advocate Patient and Public Involvement Representative	Patient Experience
Natalie Wilson	NIHR Business Development Manager	Recruitment
Rob Angus	NICE – Regulatory Experience	Quality Assurance
Klaus Schmierer	Neurological Disorders National Specialty Group	Patient Experience
David Ashford Jones	Patient and Public Involvement Representative	Recruitment
Leigh Boxall	Industry (Quintiles)	Recruitment
Gary Nestor	NIHR Cluster E	Outcome measures
Kim Down	NIHR Cluster E	Admin
Anna Moroney	NIHR Cluster E	Admin

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65



Click here to access/download
Supplementary Material
Supplementary material.docx

